Back to Screener

Healthcare

Sysmex Corporation(SSMXF)

Live Price

Offline

$8.85

+0.00% today

1Y Change

-47.16%

Window

Jun 23, 2025 โ†’ Jun 17, 2026

Market Cap
$829.76B
Revenue Growth
+10.2%
EPS Growth
+8.6%
Dividend Yield
2.9%

Coverage: 248 bars ยท Jun 23, 2025 โ†’ Jun 17, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Sysmex Corporation (SSMXF) is a Healthcare stock with a market cap of $829.76B and listed on OTC. The stock last traded around $8.85 and down 47.2% across the available one-year price window (Jun 23, 2025 โ†’ Jun 17, 2026). Baseline metrics include revenue growth of +10.2%, EPS growth of +8.6%, a dividend yield of 2.9%. What stands out right now is revenue +10.2%, EPS +8.6%, free cash flow +179.2% with operating margin 14.0% and ROIC 8.1%. The dividend matters to the case here, with a current yield around 2.9%. Valuation is more restrained than many high-expectation growth names at P/E 18.5 and price/sales 1.6. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SSMXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+10.2% vs +7.6% peer median

Operating Margin

Below sector median

+14.0% vs +19.4% peer median

P/E

Below sector median

18.5 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

The operating story is still moving forward

Revenue is running at +10.2% and EPS at +8.6%, with operating margin around 14.0%.

Shareholder return is still part of the story

The stock is still offering a dividend yield around 2.9%, which matters if the thesis depends on income as much as growth.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

SSMXF

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

SSMXF Max Drawdown

-52.45%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for SSMXF and SPY.

Calendar-year return history is still loading or unavailable.
Sysmex Corporation logo

Company Overview

Sysmex Corporation

Other OTC

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Leadership
Hisashi Ietsugu
IPO Date
Apr 21, 2009
Employees
10.0k
Street Address
1-5-1 Wakinohama-kaigandori
Mailing
Kobe, 651-0073
Region
Kobe, JP
Reporting Currency
USD
Investor Line
81 78 265 0500
Last Updated
May 5, 2026
CIK: 0001517231ISIN: JP3351100007
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
18.5
EV/EBITDA
7.1
Price/Sales
1.6
Price/Book
1.7

Growth

Revenue
+10.2%
EPS
+8.6%
Free Cash Flow
+179.2%

Profitability

Gross Margin
51.9%
Operating Margin
14.0%
Net Margin
8.9%
ROE
9.4%
ROIC
8.1%

Balance Sheet

Debt/Equity
0.14
Current Ratio
3.33

Earnings Reports

No earnings data available

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.